';
CLOSE
Tags Posts tagged with "DDAP"

DDAP

0 1428

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) awarded $4 million in grant funding for the establishment of regional recovery hubs to enhance resources for individuals in recovery and promote recovery within communities across Pennsylvania.

The funding will allow each regional recovery hub to conduct an initial needs assessment for recovery support services in their specific region, including an estimate of individuals in need of these services and an analysis of their availability and accessibility. In addition, the hubs will develop a strategic plan, partnering with local organizations, that focuses on the importance of supporting multiple pathways to and through recovery, and will seek to promote recovery services in areas including peer support, family support, and self-care.

The regional recovery hubs throughout Pennsylvania will be designed to embed, expand, and promote a Recovery-Oriented-System of Care, which is a coordinated network of community-based services and supports that is person-centered, with the ultimate goal of improving the health, wellness, and quality of life for individuals in recovery from substance use disorder.

Grants up to $500,000 each will be awarded for the 15-month period beginning July 1, 2023, through September 29, 2024, to the following organizations serving the various regions:

  • The Council of Southeast Pennsylvania (serving Philadelphia, Montgomery, Bucks, Berks, Chester, Lancaster, Delaware, and Schuylkill Counties);
  • Unity Recovery (serving Allegheny County);
  • County of Erie Office of Drug & Alcohol Abuse (serving Erie County);
  • Armstrong Indiana Clarion Drug & Alcohol Commission, Inc. (serving Beaver, Butler, Armstrong, Indiana, Cambria, Washington, Westmoreland, Greene, Fayette, and Somerset, Crawford, Mercer, Lawrence, Venango, Warren, Forest, Clarion, McKean, Elk, Cameron, Jefferson, and Clearfield Counties);
  • West Branch Drug & Alcohol Abuse Commission (serving Potter, Tioga, Bradford, Clinton, Lycoming, Sullivan, Centre, Union, Snyder, Montour, Columbia, and Northumberland Counties); and
  • Northbound & Co. (serving Susquehanna, Wayne, Wyoming, Lackawanna, Luzerne, Carbon, Monroe, Pike, Lehigh, and Northumberland Counties).

Each grantee will use a hub and spoke model to provide recovery supports in their designated region. Each regional “hub” will support community-driven services that will serve as “spokes.” The hub will provide technical assistance and collaborate with a variety of community entities, sectors, and systems to enhance a recovery-supportive community and facilitate recovery support service delivery.

In addition, DDAP issued a Grant Initiative Funding Application (GIFA) for a regional recovery hub in Region 5, which includes York, Adams, Franklin, Fulton, Bedford, Cumberland, Perry, Dauphin, Lebanon, Huntington, Mifflin, Juniata, and Blair Counties.

The GIFA is available on DDAP’s website.

0 1658

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) will offer an instructor-led, two-hour training titled, “Xylazine: A New Drug Additive.” Savage Sisters Recovery, a Pennsylvania nonprofit that provides trauma-informed recovery housing, harm reduction, outreach, and statewide education, will lead the training.

According to a recent New York Times article, “In Philadelphia, and increasingly in drug hot zones around the country, an animal tranquilizer called xylazine — known by street names like ‘tranq,’ ‘tranq dope’ and ‘zombie drug’ — is being used to bulk up illicit fentanyl, making its impact even more devastating.

“Xylazine causes wounds that erupt with a scaly dead tissue called eschar; untreated, they can lead to amputation. It induces a blackout stupor for hours, rendering users vulnerable to rape and robbery. When people come to, the high from the fentanyl has long since faded and they immediately crave more. Because xylazine is a sedative and not an opioid, it resists standard opioid overdose reversal treatments.”

This instructor-led training will provide information on national and statewide opioid statistics and updates on current drug supply trends, including critical information on xylazine. A demonstration of overdose reversal procedures when the presence of xylazine is suspected is also included in this training.

DDAP is holding two sessions of this training at its office in Harrisburg on May 25, 2023. Please visit DDAP’s Training Management System for details and to register. Pennsylvania Certification Board continuing education credits will be available for these sessions.

0 668

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) is seeking provider input for a brief workforce survey. DDAP is interested in hearing providers’ perspective on which jobs and positions are in short supply or understaffed, the challenges providers face, attempts to address them, and solutions that DDAP should consider. Responses will help inform DDAP’s regulatory reform efforts.

The survey can be taken here.

0 2475

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) today announced almost $9 million in grant funding awarded to four Single County Authorities (SCAs) to establish or expand crisis stabilization services for individuals with co-occurring mental health and substance use disorders (SUD). The funding is part of the more than $17 million allocated last year to DDAP by the General Assembly from Pennsylvania’s share of a total opioid settlement of $1.2 billion reached with three distributors and manufacturer Johnson & Johnson.

Crisis stabilization services include assessment and stabilization of acute physical and psychiatric symptoms, which may include medical management and behavioral interventions, induction on medications for opioid use disorder, level of care assessments, short-term stays, and connections to supportive services.

Grants up to $3 million each will be awarded to the following four SCAs, serving residents throughout seven counties:

  • Dauphin County Drug and Alcohol Services;
  • Bucks County Drug and Alcohol Commission;
  • Delaware County Department of Human Services; and
  • Blair County Drug and Alcohol Program.

The funding can be applied toward a range of activities, including construction and building infrastructure, staffing, and programming. DDAP’s goal in offering this funding opportunity is to provide an additional mechanism for counties to invest in infrastructure, staffing, programming, and other necessary components to establish or expand crisis stabilization services.

Eligible grantees were chosen based on information presented in their applications demonstrating their capacity to recognize and manage individuals presenting with a wide range of SUD-related symptoms, mental health disorders, and developmental disabilities.

0 1998

Effective January 1, Act 111 of 2022 amended the Controlled Substance, Drug, Device, and Cosmetic Act of 1972 to no longer define fentanyl test strips (FTS) as drug paraphernalia in Pennsylvania, making them a legal, low-cost method to prevent drug overdoses.

The Pennsylvania Departments of Drug and Alcohol Programs, Health, and Human Services, and the Pennsylvania Commission on Crime and Delinquency have created a survey to gauge interest in and demand for FTS as the administration works to make them available at no cost across the commonwealth. The survey contains questions on currently available trainings/materials, preferred brands, and current distribution methods and takes about five minutes to complete.

Organizations are urged to complete the survey here and to distribute the link to others.

0 3073

On January 30, the Biden Administration announced that the COVID-19 national emergency and public health emergency (PHE) will both expire on Thursday, May 11, 2023. Under Act 30 of 2022, the Department of Drug and Alcohol Programs’ (DDAP) regulatory suspensions that are “related to federal exemptions granted under the federal public health emergency declaration” were extended until “the last day federal exemptions granted under the federal public health emergency declaration are authorized.” In other words, Act 30 aligned the timing for DDAP’s regulatory suspensions with the deadline for flexibilities granted by the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Drug Enforcement Administration (DEA) — not with the deadline of the PHE itself.

Below is a description of each currently suspended regulation and what DDAP knows about efforts to make these changes permanent at the federal level.

Methadone Take-Home Supply

Current regulatory suspension: Under the federal PHE, SAMHSA is currently allowing up to 28 days of take-home medications for patients on stable dosages, as deemed appropriate by their physician. DDAP’s regulation 28 Pa. Code § 715.16(e) (prohibiting narcotic treatment programs [NTPs] from permitting a patient to receive more than a two-week take-home supply) is currently suspended under Act 30.

Expiration of the PHE: In November 2021, SAMHSA announced that the methadone take-home flexibilities will be extended for one year after the end of the PHE (now May 11, 2024). DDAP submitted its written concurrence with this exemption in February 2022. Furthermore, SAMHSA issued a notice of proposed rulemaking in December 2022 that proposes modifying regulations related to methadone take-home supply up to 28 days, among other changes.

Buprenorphine Telehealth

Current regulatory suspension: Under the federal PHE, SAMHSA and the DEA are currently allowing initial evaluations for a patient who will be treated with buprenorphine to be completed via telehealth. DDAP has two related regulations that are currently suspended under Act 30:

  • 28 Pa. Code § 715.9(a)(4): Requires NTPs to make a face-to-face determination before admission to treatment for those clients who will receive medication to treat opioid use disorder (OUD).
  • 28 Pa. Code § 715.6(d): Requires NTPs to have narcotic treatment physician services onsite.

Expiration of the PHE: In March 2022, the DEA announced that it is currently working to make its teleprescribing regulations permanent. In June 2022, SAMHSA announced to State Opioid Treatment Authorities that flexibilities around telehealth evaluations before buprenorphine treatment at NTPs, specifically, will be extended for one year after the end of the PHE (now May 11, 2024).

SAMHSA and DEA have made clear that support for these flexibilities has been overwhelmingly positive, decreased stigma associated with OUD, and enhanced care for patients. Given the information above, DDAP does not anticipate any lapses in these flexibilities at either the federal or state level but will continue to provide updates and guidance as available.

Resources

If you have any further questions, please contact the Bureau of Program Licensure at (717) 783-8675 or via email.

0 1706
Photo by Markus Winkler from Pexels

Former Department of Drug and Alcohol Programs (DDAP) Secretary Jennifer Smith has been named Deputy Secretary for the Office of Mental Health and Substance Abuse Services (OMHSAS). As DDAP Secretary, Smith led DDAP’s efforts to fulfill its mission of engaging and coordinating the commonwealth’s efforts to prevent and reduce substance use disorder and problem gambling and to promote recovery. Smith was integral in the formation and implementation of Pennsylvania’s first licensure program for recovery houses as well as leading Pennsylvania’s treatment system transition away from the Pennsylvania Client Placement Criteria to ASAM Criteria.

Dr. Dale Adair, who has served as Acting Deputy Secretary for OMHSAS, will continue to serve as the Chief Psychiatric Officer for OMHSAS.

Prev1...456...16Next Page 5 of 16
© 2021 - Rehabilitation & Community Providers Association